Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia

被引:0
作者
Haya Ascher-Svanum
Baojin Zhu
Douglas Faries
Ron Landbloom
Marvin Swartz
Jeff Swanson
机构
[1] Lilly Research Laboratories,Department of Psychiatry and Behavioral Sciences
[2] Eli Lilly and Company,undefined
[3] Duke University Medical Center,undefined
来源
BMC Psychiatry | / 6卷
关键词
Haloperidol; Clozapine; Risperidone; Olanzapine; Quetiapine;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 228 条
[1]  
Herz MI(1991)Intermittent vs. maintenance medication in schizophrenia: two-year results Arch Gen Psychiatry 48 333-339
[2]  
Glazer WM(2004)Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia Psychiatr Serv 55 886-891
[3]  
Mostert MA(2003)Atypical antipsychotics in first admission schizophrenia: medication continuation and outcomes Schizophr Bull 29 519-530
[4]  
Sheard MA(2001)Using drug claims data to assess the relationship of medication adherence with hospitalization and costs Psychiatr Serv 52 805-811
[5]  
Szymanski HV(2003)An economic review of compliance with medication therapy in the treatment of schizophrenia Psychiatr Serv 54 508-516
[6]  
Hafez H(1998)Compliance with medication regimens for mental and physical disorders Psychiatr Serv 49 196-201
[7]  
Mirza M(2000)Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis BMJ 321 1371-1376
[8]  
Vana J(2003)A meta-analysis of the efficacy of second-generation antipsychotics Arch Gen Psychiatry 60 553-564
[9]  
Weiden PJ(2001)Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta analysis of randomized trials Am J Psychiatry 158 518-526
[10]  
Kozma C(2003)Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials Am J Psychiatry 160 1209-1222